Zio XT, a wearable heart monitor developed by digital healthcare company iRhythm was tested in the GUARD-AF study. The study results showed that the Zio XT increased atrial fibrillation (AFib) diagnoses by 52% compared to standard care, with diagnosis rates of 5.0% vs. 3.3% over an average 15-month follow-up period.
The study involved nearly 12,000 patients aged 70 or above across the US and aimed to compare the device's effectiveness in detecting AFib against regular care. The Zio XT is a lighter, more discreet alternative to traditional Holter monitoring, allowing patients to wear the device for two weeks, enabling longer-term electrocardiogram monitoring.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.